top of page

RSV Vaccine

Overview

​

A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine in Adults ≥ 50 Years of Age

​

Do you Qualify?

​These statements require a yes answer to qualify.​

​

  • 1. Adults ≥ 50 years of age on the day of the Randomization Visit who are primarily responsible for self-care and activities of daily living. 

  • 2. Willing and able (on both a physical and cognitive basis) to give informed consent prior
    to study enrollment.

  • 3. Able to comply with study requirements, including access to transportation for study
    visits.

​​​

2. Known history of poorly controlled hypertension (per determination of the investigator), or systolic blood pressure > 160 mmHg at the Screening or baseline (Day 1) visit.

3. Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤ 28 days prior to study injections (Day 1) or plans to receive a vaccine

authorized or approved by a local health agency within 28 days after the study injections.

4. Participant has received a seasonal influenza vaccine or any other investigational

influenza vaccine ≤ 180 days prior to the Randomization Visit.

5. Participant has tested positive for influenza by local health authority approved testing

methods ≤ 180 days prior to the Screening Visit.

If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.

​

​

bottom of page